First targeted therapy for rare T-cell lymphoma after CAR T treatment successful

A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma, marking a first in the field of hematologic cancer research. The findings were published in the New England Journal of Medicine.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup